ELAVL1 Human shRNA Plasmid Kit (Locus ID 1994)

CAT#: TL313235

ELAVL1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL313235A virus into HEK293 cells. TL313235A virus was prepared using lenti-shRNA TL313235A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL313235B virus into HEK293 cells. TL313235B virus was prepared using lenti-shRNA TL313235B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL313235C] virus into HEK293 cells. [TL313235C] virus was prepared using lenti-shRNA [TL313235C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL313235D] virus into HEK293 cells. [TL313235D] virus was prepared using lenti-shRNA [TL313235D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 1994
• Synonyms: ELAV1; Hua; HUR; MelG
• Vector: pGFP-C-shLenti
• E. coli Selection: Chloramphenicol
• Mammalian Cell Selection: Puromycin
• Format: Lentiviral plasmids
• Kit Components: ELAVL1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 1994). 5µg purified plasmid DNA per construct
  Non-effective 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
• RefSeq: NM_001419, NM_001419.1, NM_001419.2, BC003376, BC003376.2, BM664469, BM696191, NM_001419.3
• UniProt ID: Q15717
• Summary: The protein encoded by this gene is a member of the ELAVL family of RNA-binding proteins that contain several RNA recognition motifs, and selectively bind AU-rich elements (AREs) found in the 3' untranslated regions of mRNAs. AREs signal degradation of mRNAs as a means to regulate gene expression, thus by binding AREs, the ELAVL family of proteins play a role in stabilizing ARE-containing mRNAs. This gene has been implicated in a variety of biological processes and has been linked to a number of diseases, including cancer. It is highly expressed in many cancers, and could be potentially useful in cancer diagnosis, prognosis, and therapy. [provided by RefSeq, Sep 2012]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).